Brii Biosciences
- Health
Brii Biosciences, Vir Biotechnology, and VBI Vaccines Announce Initiation of Phase 2 Clinical Trial of BRII-835 (VIR-2218) in Combination with BRII-179 (VBI-2601) for the Treatment of Hepatitis B
DURHAM, N.C. & BEIJING & SAN FRANCISCO & CAMBRIDGE, Mass.: Brii Biosciences (Brii Bio), Vir Biotechnology, Inc. (Nasdaq: VIR), and…
Read More » - Business
Brii Biosciences Closes US$155 Million Series C Financing
Beijing, China & Durham, N.C., United States: – Financing led by Invesco Developing Markets Fund, joined by a syndicate of new…
Read More » - Health
Brii Biosciences Appoints Rogers Luo, Ankang Li To Leadership Positions
Rogers Yongqing Luo, B.M., MBA (Photo: Business Wire) Beijing, China & Durham, N.C., United States: – Rogers Yongqing Luo, B.M., MBA,…
Read More »